InterPACIFIC project : comparison of invasive and non-invasive methods for seismic site characterization. Part I : Intra-comparison of surface wave methods

The main scope of the InterPACIFIC (Intercomparison of methods for site parameter and velocity profile characterization) project is to assess the reliability of in-hole and surface-wave methods, used for estimating shear wave velocity. Three test-sites with different subsurface conditions were chosen: a soft soil, a stiff soil and a rock outcrop. This paper reports the surface-wave methods results. Specifically 14 teams of expert users analysed the same experimental surface-wave datasets, consisting of both passive and active data. Each team adopted their own strategy to retrieve the dispersion curve and the shear-wave velocity profile at each site. Despite different approaches, the dispersion curves are quite in agreement with each other. Conversely, the shear-wave velocity profiles show a certain variability that increases in correspondence of major stratigraphic interfaces. This larger variability is mainly due to non-uniqueness of the solution and lateral variability. As expected, the observed variability in V-s,V-30 estimatesis small, as solution non-uniqueness plays a limited role

N-3 fatty acids in patients with multiple cardiovascular risk factors

BACKGROUND: Trials have shown a beneficial effect of n-3 polyunsaturated fatty acids in patients with a previous myocardial infarction or heart failure. We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction. METHODS: In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were followed by a network of 860 general practitioners in Italy. Eligible patients were men and women with multiple cardiovascular risk factors or atherosclerotic vascular disease but not myocardial infarction. Patients were randomly assigned to n-3 fatty acids (1 g daily) or placebo (olive oil). The initially specified primary end point was the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke. At 1 year, after the event rate was found to be lower than anticipated, the primary end point was revised as time to death from cardiovascular causes or admission to the hospital for cardiovascular causes. RESULTS: Of the 12,513 patients enrolled, 6244 were randomly assigned to n-3 fatty acids and 6269 to placebo. With a median of 5 years of follow-up, the primary end point occurred in 1478 of 12,505 patients included in the analysis (11.8%), of whom 733 of 6239 (11.7%) had received n-3 fatty acids and 745 of 6266 (11.9%) had received placebo (adjusted hazard ratio with n-3 fatty acids, 0.97; 95% confidence interval, 0.88 to 1.08; P=0.58). The same null results were observed for all the secondary end points. CONCLUSIONS: In a large general-practice cohort of patients with multiple cardiovascular risk factors, daily treatment with n-3 fatty acids did not reduce cardiovascular mortality and morbidity. Copyright © 2013 Massachusetts Medical Society